PET Trial to Evaluate Target Occupancy of CVL-231 on Brain Receptors Following Oral Dosing

Inclusion Criteria: * Healthy male subjects and female subjects of nonchildbearing potential, ages 18 to 55 years, inclusive, at the time of signing the ICF * Sexually active men with a pregnant or a nonpregnant partner of childbearing potential must agree to use a double-barrier method of birth control, including a condom, and practice contraception during treatment and through 7 days post dose * Capable of providing informed consent and following study requirements Exclusion Criteria: * Subjects who answer yes on the C-SSRS or, in the opinion of the investigator, present a serious risk of suicide * Subjects with a current history of significant cardiovascular, pulmonary, gastrointestinal, renal, hepatic, metabolic, hematological, immunological, or neurological disease * Subjects with a 12-lead ECG demonstrating either of the following (average of 3 ECGs obtained at the Screening Visit): * QT interval corrected for heart rate using Fridericia's formula \>450 msec * Left ventricular hypertrophy * Orthostatic hypotension, which is defined as a decrease of ≥20 mmHg in systolic blood pressure and/or a decrease of ≥10 mmHg in diastolic blood pressure after at least 3 minutes of standing compared with the immediately previous supine/semi-recumbent blood pressure at Screening or at the prescan time point prior to baseline PET scan. * Subjects with a current or past personal history of any psychiatric disorder as classified by DSM-5 criteria or immediate family members with …